Company Filing History:
Years Active: 2019-2025
Title: The Innovative Contributions of Mitchell H. Finer
Introduction
Mitchell H. Finer is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of oncolytic viral therapies for cancer treatment. With a total of 6 patents to his name, Finer's work has the potential to revolutionize cancer therapies.
Latest Patents
Finer's latest patents focus on innovative approaches to cancer treatment using oncolytic viral vectors. One of his notable patents describes oncolytic viral vectors that incorporate features such as viral replication restriction through the insertion of microRNA (miRNA) target sequences into the viral genome. This technology aims to disrupt oncogenic miRNA function, remodel the cancer microenvironment, and target cancer cells by incorporating protease-activated antibodies into the viral particle. These viral vectors can be utilized for both the treatment and prevention of cancer. Another significant patent details oncolytic viruses that comprise nucleic acids encoding an engager molecule, which can be combined with therapeutic molecules. This advancement includes pharmaceutical compositions containing the oncolytic virus and methods for treating cancer using these innovative viruses.
Career Highlights
Throughout his career, Finer has worked with notable companies in the biotechnology sector, including Oncorus, Inc. and Virogin Biotech Canada Ltd. His experience in these organizations has allowed him to further develop his expertise in oncolytic viral therapies and contribute to groundbreaking research in cancer treatment.
Collaborations
Finer has collaborated with esteemed colleagues such as Kenneth P. Greenberg and Lorena Lerner. These partnerships have fostered a collaborative environment that enhances the development of innovative cancer therapies.
Conclusion
Mitchell H. Finer's contributions to the field of biotechnology, particularly in oncolytic viral therapies, demonstrate his commitment to advancing cancer treatment. His innovative patents and collaborations highlight the potential for significant breakthroughs in the fight against cancer.